Rapacuronium



This article or section relies largely or entirely upon a single source.
Please help improve this article by introducing appropriate citations of additional sources.
Rapacuronium bromide
Systematic (IUPAC) name
[(2S,3S,5S,8R,9S,10S,13S,14S,16S,17S)-
3-acetyloxy-10,13-dimethyl-2-(1-piperidyl)-16-
(1-prop-2-enyl-3,4,5,6-tetrahydro-2H-pyridin-
1-yl)-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-
1H-cyclopenta[a]phenanthren-17-yl]propanoate
Identifiers
CAS number 156137-99-4
ATC code  ?
PubChem 5311398
Chemical data
O4+
Mol. mass 597.891 g/mol
Pharmacokinetic data
Bioavailability Not applicable
Protein binding Variable
CYP system not involved
Half life 141 minutes (mean)
Excretion Renal and fecal
Therapeutic considerations
Pregnancy cat.

C(US)

Legal status

Withdrawn (U.S)

Routes Intravenous

Rapacuronium bromide (trade name Raplon, neuromuscular blocker used in modern anaesthesia, to aid and enable endotracheal intubation, which is often necessary to assist in the controlled ventilation of unconscious patients during surgery and sometimes in intensive care. As a non-depolarizing agent, it does not cause initial stimulation of muscles before weakening them.

Due to risk of fatal bronchospasm, it was withdrawn from the United States market by the manufacturer on March 27, 2001.[1]

References

  1. ^ Shapse, Deborah (March 27, 2001). Voluntary Market WithdrawalPDF (10.8 KiB). Organon International. Retrieved on 2007-04-02.
 
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Rapacuronium". A list of authors is available in Wikipedia.